Group 1 - The company Guangxi Wuzhou Zhongheng Group Co., Ltd. announced that its subsidiary Chongqing Laimei Pharmaceutical Co., Ltd. and its wholly-owned subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd. participated in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected for procurement [1][2] - The selected products are projected to generate a total sales revenue of 106.19 million yuan in 2024, accounting for 4.68% of the company's total revenue for that year. For the first three quarters of 2025, the expected sales revenue is 66.07 million yuan, representing 3.39% of the company's revenue for that period [1][2] Group 2 - The procurement is organized by a national alliance consisting of various provinces and regions, with Jiangsu, Henan, and Guangdong provinces leading the initiative. The procurement aims to ensure that medical institutions prioritize the selected products, which is expected to enhance sales and market expansion for the company [2]

Core Viewpoint - Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd. (referred to as "Laimei Pharmaceutical"), and its wholly-owned subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd. (referred to as "Hunan Kangyuan"), participated in the national centralized procurement for drugs whose agreements have expired, indicating potential selection for procurement which could enhance sales and market expansion [1] Group 1 - Laimei Pharmaceutical and Hunan Kangyuan participated in the bidding organized by the National Centralized Procurement Office for drugs with expired agreements [1] - The procurement is led by a coalition of provinces and regions, including Jiangsu, Henan, and Guangdong, focusing on products from the first eight batches of the national centralized procurement [1] - If procurement agreements are signed and implemented, it will positively impact the sales and brand influence of the selected products, contributing to the long-term development of the company [1]

证券代码：600252 证券简称：中恒集团 公告编号：临 2026-14 | 拟中选企业 | 品种名称 | 适应症 | | --- | --- | --- | | 重庆莱美药业 | 常释剂型 剂 | 胃食管反流病，急性胃或十二指肠溃疡出血，降低成 | | | 培美曲塞注射剂 埃索美拉唑（艾司奥美拉唑）口服 | 治疗非小细胞肺癌和恶性胸膜间皮瘤。 胃食管反流病，与适当的抗菌疗法联合用药根除幽门 | | | | 螺杆菌，与使用非甾体抗炎药治疗相关的胃溃疡治疗。 | | | 埃索美拉唑（艾司奥美拉唑）注射 | | | | | 人胃和十二指肠溃疡出血内镜治疗后再出血风险，预 | | | | 防重症患者应激性溃疡出血。 | | | 替米沙坦口服常释剂型 | 成年人原发性高血压的治疗。 | | 股份有限公司 | 伏立康唑口服常释剂型 | 治疗成人和 2 岁及 2 岁以上儿童患者的真菌感染。 | | | 紫杉醇注射剂 | 治疗卵巢癌、乳腺癌、晚期非小细胞肺癌、以及艾滋 | | | | 病相关性卡波氏肉瘤。 | | | 甲泼尼龙注射剂 | 除非用于某些内分泌疾病的替代治疗，糖皮质激素仅 | | | | 仅是一种对症治疗的药物 ...

Group 1 - The core viewpoint of the news is that Zhongheng Group (600252) anticipates a net profit loss of 250 million to 450 million yuan for the fiscal year 2025, primarily due to a decline in core business, impairment provisions, and losses from non-operating income [1] - The company’s subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd., received approval for a supplementary application for sodium lactate Ringer's injection, which may enhance its market competitiveness [1] Group 2 - On February 10, 2026, Zhongheng Group announced the absorption merger of its wholly-owned subsidiary Nanning Shuangqian by its holding subsidiary Shuangqian Industry, aimed at improving operational efficiency, reducing management costs, and optimizing resource allocation [2] - Following the merger, Nanning Shuangqian's legal status will be canceled, and its related assets and liabilities will be inherited by Shuangqian Industry, with no significant asset restructuring or payment required [2] Group 3 - Over the past week (February 7 to 13, 2026), Zhongheng Group's stock price has shown a downward trend, closing at 2.55 yuan on February 13, down 1.16% from 2.60 yuan on February 9, with a price fluctuation of 3.10% [3] - Trading volume peaked at 87.37 million yuan on February 12 but decreased to 52.19 million yuan on February 13, with a net inflow of 4.3975 million yuan on that day, indicating the stock is trading between a resistance level of 2.68 yuan and a support level of 2.52 yuan [3] - The overall performance of Zhongheng Group is weaker than the pharmaceutical and biotechnology sector, which saw a decline of 0.64% during the same period [3] Group 4 - Institutional interest in Zhongheng Group is low, with a neutral sentiment prevailing in the market; there have been no institutional surveys, and 100% of institutional ratings are neutral, with a fund holding ratio of only 0.01% [4] - Profit forecasts indicate an earnings per share of -0.11 yuan for 2024, reflecting a year-on-year decline of 547.14%, highlighting fundamental pressures on the company [4] - No recent targeted research reports have been published by brokerage firms regarding Zhongheng Group [4]

股票简称 股票代码 限售股类型 解禁股数 中恒集团 600252 股权激励限售流通 1090.55万 智通财经APP获悉，2月11日共有1家上市公司的限售股解禁，解禁总市值约2497.36万元。 今日具体限售解禁股情况如下： ...

本次交易的吸收合并双方分别为公司控股子公司、控股孙公司，本次吸收合并后，公司注册资本不变， 无需支付对价。本次吸收合并事项不构成关联交易，也不构成《上市公司重大资产重组管理办法》规定 的重大资产重组情形。无需提交公司股东会审议 为进一步提高运营效率、降低管理成本、优化资源配置，公司控股子公司双钱产业吸收合并其全资子公 司南宁双钱。吸收合并完成后，南宁双钱不再存续，其独立法人资格将被注销，全部资产、债权债务及 其他一切权利与义务由双钱产业依法承继。 格隆汇2月10日丨中恒集团(600252.SH)公布，2026年2月9日，公司第十届董事会第三十六次会议审议通 过《广西梧州中恒集团股份有限公司关于广西双钱健康产业股份有限公司吸收合并南宁中恒双钱实业有 限公司的议案》，董事会同意由公司控股子公司双钱产业吸收合并其全资子公司南宁双钱。现将有关情 况公告如下： ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2026-13 广西梧州中恒集团股份有限公司 关于控股子公司广西双钱健康产业股份有限公司吸收 合并其全资子公司南宁中恒双钱实业有限公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）控 股子公司广西双钱健康产业股份有限公司（以下简称"双钱产业"）拟吸收合并 其全资子公司南宁中恒双钱实业有限公司（以下简称"南宁双钱"）。 ●本次吸收合并事项不涉及公司注册资本变更，无需支付对价，不构成关联 交易，也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情形。 ●被合并方为公司控股孙公司，其财务报表已纳入公司的合并报表范围，故 本次吸收合并不会对公司财务状况、经营成果、业务发展产生不利影响，也不会 对公司的当期损益产生实质性影响，不会损害公司及全体股东的利益。 为进一步提高运营效率、降低管理成本、优化资源配置，公司控股子公司双 钱产业吸收合并其全资子公司南宁双钱。吸收合并完成后，南宁双钱 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2026-12 广西梧州中恒集团股份有限公司 关于政府收储控股孙公司土地事项进展 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）控股 孙公司肇庆中恒制药有限公司（以下简称"肇庆中恒制药"）拟与肇庆高新技术 产业开发区土地储备中心（以下简称"肇庆高新区土储中心"）签署肇庆高新区 土地收储相关补充协议。 ●特别风险提示：截至本公告披露日，相关补充协议目前尚未签署，肇庆高 新区土储中心尚需履行政府相关部门的审批程序。因此，各方最终能否签署尚存 在不确定性。敬请广大投资者谨慎决策，注意投资风险。 一、土地收储的基本情况 （一）基本情况 2021 年 8 月 27 日，公司召开第九届董事会第二十九次会议，会议审议通过 《广西梧州中恒集团股份有限公司关于控股孙公司肇庆中恒制药有限公司和肇 庆中恒双钱实业有限公司土地由政府收储的议案》，同意控股孙公司肇庆中恒制 药和肇庆中恒双钱实业有限公司（以下简 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2026-11 广西梧州中恒集团股份有限公司 第十届董事会第三十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）第十 届董事会第三十六次会议通知和议案材料于 2026 年 2 月 4 日以电子邮件的方式 发出，会议于 2026 年 2 月 9 日以现场结合通讯方式在广西南宁市江南区高岭路 100 号办公楼会议室召开，公司董事长杨金海先生现场出席并主持会议，董事王 靓女士、王海润先生，独立董事陈道峰先生、龚行楚先生、李骅先生出席现场会 议，董事杨绍孙先生、刘龙先生以通讯方式出席。会议应当出席董事 8 人，实际 出席会议董事 8 人。会议的召集和召开符合《公司法》《公司章程》和《公司董 事会议事规则》的有关规定。 二、董事会会议审议情况 （一）会议审议通过《广西梧州中恒集团股份有限公司关于政府收储控股孙 公司土地事项签订补充协议的议案》； 董事会同意公司控股孙公司与肇庆土 ...

Group 1 - The core point of the article is that Zhongheng Group announced the approval of a supplemental application for Sodium Lactate Ringer's Injection (500ml) by its subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd. from the National Medical Products Administration [2] Group 2 - The approval signifies a regulatory milestone for Hunan Kangyuan Pharmaceutical, enhancing its product portfolio in the pharmaceutical market [2] - This development may lead to increased market competitiveness and potential revenue growth for the company [2] - The product is expected to meet the growing demand for intravenous solutions in clinical settings [2]